Anzeige
Mehr »
Sonntag, 26.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XE7A | ISIN: CA4990531069 | Ticker-Symbol: 04K
Frankfurt
24.10.25 | 08:34
3,600 Euro
+1,12 % +0,040
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KNIGHT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KNIGHT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,5603,62019:04
3,5803,60024.10.

Aktuelle News zur KNIGHT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.10.Knight Therapeutics Inc: Knight Therapeutics relaunches Orgovyx in Canada1
07.10.Knight Therapeutics Inc: Knight Therapeutics relaunches Myfembree in Canada1
07.10.Knight Therapeutics Announces Relaunch of MYFEMBREE in Canada4
07.10.Knight Therapeutics Announces Relaunch of ORGOVYX in Canada223MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX®...
► Artikel lesen
26.09.Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies1
20.08.Knight Therapeutics Inc: Knight Therapeutics receives TSX approval for NCIB2
20.08.Knight Therapeutics announces share buyback plan1
20.08.Knight Therapeutics: Knight Announces Normal Course Issuer Bid3
KNIGHT THERAPEUTICS Aktie jetzt für 0€ handeln
07.08.Knight Therapeutics Reports Second Quarter 2025 Results581Achieved record-high quarterly revenues since inceptionIncreased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company")...
► Artikel lesen
06.08.Knight Therapeutics Inc: Knight submits Crexont Parkinson's drug in Mexico1
05.08.Knight Therapeutics Announces Regulatory Submission of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Mexico314MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo...
► Artikel lesen
04.08.Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America261MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing...
► Artikel lesen
01.08.Knight Therapeutics Inc: Knight Therapeutics to release Q2 results Aug. 72
01.08.Knight Therapeutics Inc: Knight submits supplemental application for Minjuvi1
31.07.Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI (tafasitamab) for Follicular Lymphoma in Brazil749MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
► Artikel lesen
18.07.Knight Therapeutics Inc: Knight files new drug submission for Crexont in Canada2
18.07.Stocks in Play: Knight Therapeutics Inc.-
18.07.Knight Therapeutics Announces Filing of New Drug Submission for CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Canada223MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission...
► Artikel lesen
18.06.Knight Therapeutics Inc: Knight Therapeutics closes Paladin acquisition1
17.06.Knight Therapeutics Inc: Knight secures $50M (U.S.) revolving credit facility2
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1